With thousands of deaths across the globe and the world in the midst of an economic shutdown, the race is on to create a COVID-19 vaccine, and a medical research lab in Kansas City has become ground zero for coronavirus vaccination testing.
In April, Inovio Pharmaceuticals became the second U.S. company to begin human trials for a COVID-19 vaccine. The trials involve 40 healthy volunteers at two sites, one in Philadelphia and the other in Kansas City at the Center for Pharmaceutical Research, an AMR company.
The novel DNA-based vaccine, created by Inovio researchers at their San Diego lab soon after China published the virus’ genetic code, is designed to trigger an immune response to COVID-19.
Results of the trials are expected later this summer. If successful, a sufficient supply of vaccine doses is possible by the end of the year for further trials and emergency use.
Join Dr. Laurent Humeau, Chief Scientific Officer at Inovio, and Dr. John Ervin, President and Principal Investigator at the Center for Pharmaceutical Research, for an insider’s look at the COVID-19 vaccine trials underway in Kansas City that could end the pandemic and save countless lives.